The role of PI 3-kinase/AKT/mTOR and interacting pathways in haematological cancers

在这项提案中，领先的制药公司阿斯利康与伦敦圣巴塞洛缪S医院癌症研究所的两个小组合作，即实验癌症医学中心和细胞信号中心。这项建议的目的是促进新的抗癌药物进入临床，重点是白细胞癌。实验癌症医学中心在这类癌症的研究和临床试验工作方面拥有长期的专业知识。细胞信号中心在一组名为Pi 3-Kinase的分子方面拥有世界级的专业知识，这是阿斯利康旨在阻止癌细胞的新靶点。它们将共同提供新的方法来评估PI3-激酶的阻断将如何影响允许癌细胞存活和繁殖的信号的内部连接。两个团队正在共同寻找新的方法来监测药物对患者样本中PI 3-激酶的影响，更好地评估和预测潜在的反应性，以期选择可能对这些新疗法有反应的患者，并促进这些潜在的新药进入临床。

In this proposal, the leading pharmaceutical company AstraZeneca teams up with two groups at the Institute of Cancer at St Bartholomew?s Hospital in London, namely the Centre for Experimental Cancer Medicine and the Centre for Cell Signalling. The aim of this proposal is to facilitate the transition of new anti-cancer drugs into the clinic, with a focus on cancer of the white blood cells. The Centre for Experimental Cancer Medicine has a long-standing expertise in both research and clinical trial work in this type of cancer. The Centre for Cell Signalling has world-class expertise in a group of molecules termed PI 3-kinases, which are new targets that AstraZeneca is aiming to block in cancer cells. Together they will provide new methods to assess how blockade of PI 3-kinase will affect the internal wiring of signals that allow cancer cells to survive and multiply. Jointly, the teams are looking for new ways to monitor the impact of drugs againts PI 3-kinases in patient samples, to better assess and predict potential responsiveness, with a view to selecting patients that may respond to these new therapies and to facilitate entry of these potentially new drugs into the clinic.